Sydney Lupkin
Sydney Lupkin is the pharmaceuticals correspondent for NPR.
She was most recently a correspondent at Kaiser Health News, where she covered drug prices and specialized in data reporting for its enterprise team. She's reported on how tainted drugs can reach consumers, how companies take advantage of rare disease drug rules and how FDA-approved generics often don't make it to market. She's also tracked pharmaceutical dollars to patient advocacy groups and members of Congress. Her work has won the National Press Club's Joan M. Friedenberg Online Journalism Award, the National Institute for Health Care Management's Digital Media Award and a health reporting award from the Society for Advancing Business Editing and Writing.
Lupkin graduated from Boston University. She's also worked for ABC News, VICE News, MedPage Today and The Bay Citizen. Her internship and part-time work includes stints at ProPublica, The Boston Globe, The Boston Herald, The New England Center for Investigative Reporting and WCVB.
-
Using the COVID vaccine "off-label" — whether that's for booster shots or young children — may be tempting to some vaccine providers, but the CDC warns it could get them into trouble. -
Immediately after the Food and Drug Administration authorized Pfizer's vaccine, the company delivered fewer doses than its government contract projected. Federal officials say they didn't know why. -
If all goes to plan, Americans who got Pfizer or Moderna shots can get a third dose eight months after their last jab. Here's why health officials think you'll need one. -
House subcommittee members questioned why Emergent BioSoultions awarded bonuses to executives despite quality problems than hindered production of Johnson & Johnson's COVID-19 vaccine. -
President Biden threw his support behind a World Trade Organization proposal that would waive intellectual property protections for COVID-19 vaccines — allowing countries to make their own vaccines.
-
A dip of 86% in doses to be distributed to states follows a surge that occurred after one of J&J's third party manufacturers was finally able to release a stockpile. -
Johnson & Johnson has struggled with serious supply problems. Next week, states will have 86% fewer of the doses to dole out than they did this week.
-
Moncef Slaoui, who helped lead Operation Warp Speed under the Trump administration, was removed from a medical device startup's board over allegations of sexual harassment. -
Pfizer and Moderna each agreed to supply 100 million doses of COVID-19 vaccine to the U.S. by the end of March. With just under three weeks left, both companies have their work cut out for them. -
President Biden has promised enough vaccines for every U.S. adult by the end of May. But first, Pfizer and Moderna have an earlier deadline: 100 million doses each by March 31.
